GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Valuation Rank

AVCNF (Avicanna) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is Avicanna Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Avicanna Valuation Rank Related Terms

Thank you for viewing the detailed overview of Avicanna's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Valuation Rank
Comparable Companies
XCNQ:LEEF TSXV:DB XCNQ:IAN TSXV:LSL NEOE:CBST TSX:LABS TSXV:ROMJ XCNQ:CXXI XCNQ:AYR.A XCNQ:VEXT ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
0NN:Germany AVCN:Canada
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Website
https://www.avicanna.com
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.